A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED)
Latest Information Update: 10 Mar 2023
At a glance
- Drugs Dexamethasone (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Ocular Therapeutix
- 06 Mar 2023 According to Ocular media release, company plans to use the results of this study to inform the next steps for both the OTX-DED and OTX-CSI programs.
- 25 Apr 2022 According to an Ocular Therapeutics media release, data from this trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2022.
- 15 Dec 2021 Status changed from active, no longer recruiting to completed.